APELLIS PHARMACEUTICALS INC. - COMMON STOCK

Apellis Pharmaceuticals to Host Conference Call on May 4, 2023, to Discuss First Quarter 2023 Financial Results

27 апр 2023 06:00:01 Источник Nasdaq GlobeNewswire

Apellis Presents Phase 3 Functional Analyses of SYFOVRE™ (pegcetacoplan injection) for Geographic Atrophy

23 апр 2023 17:05:00 Источник Nasdaq GlobeNewswire

Apellis Announces Validation of Four Marketing Applications for Pegcetacoplan for Geographic Atrophy

21 апр 2023 06:00:00 Источник Nasdaq GlobeNewswire

Apellis Partners with Acclaimed Actor Henry Winkler to Raise Awareness of Geographic Atrophy (GA) for the GA Won’t Wait™ Campaign

17 апр 2023 06:00:00 Источник Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 апр 2023 15:05:00 Источник Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 мар 2023 15:05:00 Источник Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

01 мар 2023 06:00:02 Источник Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Option to Purchase Additional Shares

27 фев 2023 16:19:35 Источник Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

22 фев 2023 20:48:09 Источник Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

22 фев 2023 06:22:35 Источник Nasdaq GlobeNewswire

Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results

21 фев 2023 15:14:10 Источник Nasdaq GlobeNewswire

FDA Approves SYFOVRE™ (pegcetacoplan injection) as the First and Only Treatment for Geographic Atrophy (GA), a Leading Cause of Blindness

17 фев 2023 15:06:06 Источник Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

13 фев 2023 15:05:00 Источник Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 янв 2023 15:05:00 Источник Nasdaq GlobeNewswire

Apellis Appoints Leading Retina Specialist Dr. Caroline Baumal as Chief Medical Officer

05 янв 2023 06:00:00 Источник Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference

03 янв 2023 06:00:00 Источник Nasdaq GlobeNewswire

Apellis Submits Marketing Authorization Application to the European Medicines Agency for Pegcetacoplan for Geographic Atrophy

16 дек 2022 06:00:00 Источник Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

07 дек 2022 15:05:00 Источник Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

22 ноя 2022 15:05:00 Источник Nasdaq GlobeNewswire

Apellis Announces FDA Acceptance of NDA Amendment and New PDUFA Date of February 26, 2023 for Pegcetacoplan for Geographic Atrophy (GA)

18 ноя 2022 06:00:00 Источник Nasdaq GlobeNewswire